Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hernando Garcia

Pulmonary Disease Miami Beach, FL Medical Doctor

NPI 1922000314 CMS profile 360229

4302 Alton Rd, Miami Beach, FL 33140

Open in the dashboard

General payments

$18,231

273 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$61,306 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Hernando Garcia of Miami Beach, FL is reported in the CMS Open Payments database as having received $18,231 across 273 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $61,306 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,537 53
2024 General $8,812 59
2023 General $2,667 69
2022 General $3,832 43
2021 General $652 36
2020 General $418 7
2019 General $314 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hernando Garcia
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Hernando Garcia were reported at $1,537. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Hernando Garcia Pulmonary Disease median Middle half National median
2019 $314 $377 $109–$1,340 $163
2020 $418 $230 $56–$907 $114
2021 $652 $269 $68–$1,072 $132
2022 $3,832 $390 $100–$1,457 $149
2023 $2,667 $419 $114–$1,659 $160
2024 $8,812 $476 $123–$1,818 $164
2025 $1,537 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. United Therapeutics Corporation $7,944 30 payments
  2. Actelion Pharmaceuticals US, Inc. $3,740 31 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $1,546 11 payments
  4. GlaxoSmithKline, LLC. $1,239 89 payments
  5. AstraZeneca Pharmaceuticals LP $1,126 37 payments
  6. Inari Medical, Inc. $350 2 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $299 9 payments
  8. Amgen Inc. $226 9 payments
  9. Ambu Inc. $188 2 payments
  10. Stryker Corporation $184 1 payment
  11. Other $1,390 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $10,208 3 payments
  2. Food and Beverage $6,941 258 payments
  3. Travel and Lodging $800 3 payments
  4. Education $282 9 payments
Products named General payments · program years 2019–2025
  1. UPTRAVI $3,637 29 payments
  2. OPSUMIT $3,400 20 payments
  3. Adempas $1,504 9 payments
  4. TRELEGY ELLIPTA $682 45 payments
  5. FASENRA $604 24 payments
  6. CT THROMBECTOMY SYSTEM KIT $534 3 payments
  7. FLOWTRIEVER CATHETER, S $534 3 payments
  8. NUCALA $506 41 payments
  9. TYVASO $354 7 payments
  10. BREZTRI $320 8 payments
  11. Other $3,284 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,089

Median for Pulmonary Disease: 936

Drug cost

$4,508,632

Median for Pulmonary Disease: $487,987

Branded share of claims

63.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Uptravi Selexipag Brand 73 $1,706,164
Ofev Nintedanib Esylate Brand 90 $1,116,692
Letairis Ambrisentan Brand 26 $332,198
Adempas Riociguat Brand 22 $310,155
Opsumit Macitentan Brand 22 $272,925
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 295 $198,261
Adcirca Tadalafil Brand 28 $144,671
Ambrisentan Generic 60 $81,255
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 138 $70,736
Breo Ellipta Fluticasone/Vilanterol Brand 162 $66,692

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$114,686

Medicare's payments for the services billed

Medicare patients

354

Average age 78

Services billed

1,286

181 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 62%
COPD 58%
Arthritis 56%
Chronic kidney disease 50%
Heart failure 49%
Diabetes 46%
Atrial fibrillation 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca Pharmaceuticals LP $258
$258 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $172
$172 295 —
AREXVY
  • GlaxoSmithKline, LLC. $105
$105 — —
TEZSPIRE
  • Amgen Inc. $93
$93 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $90
$90 84 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record